Revolutionizing Biomedical Diagnosis with Quantum Technology

Enhancing disease detection and monitoring through advanced NV Centers Quantum Technology

Our technology

We use NV Centers in diamond for biomarker detection with unparalleled sensitivity

Machine Learning Powered Solutions

Use of machine learning techniques for signal enhancement and pattern detection

Quantum Magnetometry with NV centers

High sensitivity magnetic field reading with quantum sensors

Ultra-Sensitive Biomolecule Detection

Identify and quantify biomarkers with unprecedented precision

NV centers

NV centers are tiny defects in diamond where a nitrogen atom replaces a carbon next to a vacancy. Their electronic states interact with the environment, enabling highly sensitive and high-resolution measurements

Use cases

Our technology has a wide range of health applications

At Quanvia, we harness the power of quantum technology to revolutionize biomedical diagnostics. Our innovative approach enables early and highly precise detection of diseases, opening new possibilities for personalized medicine.

Early Disease Detection

Accurate illness detection using magnetic field sensors to identify nanoparticles.

Diagnostic support to the doctor

Assisting doctors by providing accurate data, analysis, and insights to enhance diagnosis and decision-making.

Personalized Medicine

Biomolecular interactions analysis to predict how patients will respond to specific treatments, improving therapy selection.

nT of magnetic field

µL of sample

minutes

awards received

Our efforts have been rewarded: awards that encourage us to keep growing and offering the best

NEOTEC

2nd place in NEOTEC 2024. This programme aims to finance the start-up of new business projects that require the use of technologies or knowledge developed from research activity

Start-up Biqain

This programme seeks to accelerate the development and commercialisation of quantum technology innovations in Vizcaya

Sello PYME innovadora

Acknowledgement offered by the Ministry of Science and Innovation that enhances the visibility and market credibility of SMEs

Emprende XXI Caixa

Finalist of Emprende XXI Caixa. Rewards start-ups with talent and capacity for innovation

Start-up Catapull

Acceleration programme forscientific-technological entrepreneurs

our teamMultidisciplinary team of experts in quantum technologies, biomedicine, and artificial intelligence.

Senior Computer Engineer (UPV), with an EMBA (IE), and pursuing PhD in Quantum Physics (UPV/EHU). With experience at PwC, Accenture, and Globant, he has also been a CFO, investor, and startup advisor, including at Fundeen.

Jesús Domínguez

CEO & CFO

Engineer in ICAI, with extensive experience in technology consulting and Artificial Intelligence. Ph.D. researcher in Quantum Computing.

José Rigol

CTO & COO

Research Scientist with a PhD in Biochemistry and a Master's in Molecular Biomedicine from Universidad Autónoma de Madrid. With over 6 years of experience in Cardiology, Immunology and Cancer Biology, she aims to develop impactful healthcare solutions.

Isabel Cerro

Molecular Biosciences Expert

Physics Engineering graduate with a Master's degree in Quantum Technologies from Universidad Carlos III de Madrid, experienced in quantum sensing. Enthusiastic about applying these technologies to real-world solutions.

Marta Arceiz

Quantum Technologies Specialist

Physics Engineering graduate with a Masters on Quantum Technologies from Universidad Carlos III de Madrid. Specialized in quantum sensing and NVs with lab experience on optoelectronics at companies of the quantum technologies sector.

Alfonso Fernández

Quantum Technologies Specialist

our collaborators

PhD in Physics in 2010 from Complutense University of Madrid (UCM). Postdoctoral researcher at MIT (2011–2014) and Associate Professor of Physics at UCM since 2017. Research focused on medical imaging (PET, CT, ultrasound), high-performance computing, and AI in medicine.

Joaquín López

Expert in AI applied to Medicine

PhD in Biology and Ikerbasque Research Associate Professor at the Faculty of Medicine of the University of the Basque Country (UPV/EHU). Her research focuses on applying “omics” techniques to ocular fluids to identify biomarkers for early detection and monitoring of ocular and neurodegenerative diseases.

Arantxa Acera